|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 481.00 CHF | -0.72% |
|
-4.60% | -10.56% |
| 09/03 | Lonza Extends Long-term Production Tie-up for Genetix's Gene Therapy | MT |
| 09/03 | Lonza Group and Genetix Biotherapeutics extend commercial manufacturing agreement for Zynteglo | RE |
Published on 01/28/2026 at 11:18 am IST - Modified on 01/28/2026 at 11:48 am IST
Jan 28 - Lonza, the world's largest contract drug manufacturer, on Wednesday set 2026 targets for its contract development and manufacturing organization (CDMO) business, expecting sales growth of 11% to 12% at constant exchange rates and core profit margin expansion to above 32% of sales.
The Swiss company added it expected sales growth to be higher in the first half of 2026 than in the second half.
(Reporting by Bernadette Hogg and Orest Dovhan in Gdansk, editing by Milla Nissi-Prussak)
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
